Keywords

• intermediates
• novel and diverse
• high-standard quality

Quick Details

• ProName: (4-METHYLPYRIMIDIN-5-YL)BORONIC ACID P...
• CasNo: 1370001-96-9
• Molecular Formula: C11H17BN2O2
• Application: pharmaceutical industry
• DeliveryTime: According to customer requirements
• PackAge: bags;bottles
• Port: in China
• ProductionCapacity: Metric Ton/Day
• Purity: 100%
• Storage: Keep it in cool and dry places.
• Transportation: According to customer requirements
• LimitNum: 1 Kilogram
• Heavy metal: ＜1%
• Grade: Pharma Grade

Superiority

Our R&D center is located in the Hongqiao Science andTechnology Innovation Park, Songjiang District, Shang-hai. The center is fully operated with four chemicalsynthesis laboratories and two kilo-lab laboratories.Our production facilities, located in Shandong, Jiang-su, and Hebei, are capable of handling the productionof advanced pharmaceutical intermediates, rangingfrom 100 kg to metric tons. Over years of dedicatedeffort, FDC has successfully synthesized thousands ofnew molecules and advanced pharmaceutical inter-mediates.And beyond that, we have capability tooffer over 100,000 research chemicals to clientsworldwide. We have established long-term partner-ship with pharmaceutical companies and researchinstitutes globally in Asia, Europe and North Americaetc. We have gained reputation in the industry as anexpertise in custom synthesis, contract research andmanufacturing with efficient operations and high-stan-dard quality control.

KEY CAPABILITIES
Years of unswerving commitment have empowered our R&D team to master pivotal core technologies andsecure essential patents. Our prowess extends to a robust command over R&D. pilot testing. and scale-upamplification in domains like pyridine, pyrimidine, and other heterocyclic compounds. Our dynamic team ofproficient professionals and experts serves as the cornerstone of our positive feedback loop within the R&Dindustrial chain. This dynamic ecosystem fortifies the bedrock upon which our diversified enterprises thriveensuring a trajectory of sustainable qrowth and innovation.

Details

Established in 2010,SHANGHAI FDC-CHEMICALCO.,LTD, specializes in developing pharmaceuti-calsmall molecules and offers CRO &CDMOservices for the global pharmaceutical industry.We provide chemistry services from early drugR&D stage to commercial production, includingsmall scale building block synthesis, pilot-scaleand commercial manufacturing. Our goal is toexpedite the journey of our pharmaceutical partnersfrom preclinical phases to commercial production, byproviding such advanced products and services to theglobal industry.

Our unwavering pursuit is to achieve "Seamlesscollaboration with clients, effective communication,and fulfilling our mission." In the future, FDC willpersist in its business philosophy of "innovation" and"mutually beneficial cooperation," deeply engaging inthe research, development, services, and commercialproduction of novel molecular drugs. We aim to collab-orate with partners worldwide to foster excellence.

Our R&D Center, with space over 1700 square meters.has four fully equipped chemical synthesis laboratoriesand two kilo-lab units. Our dedicated team of over 30researchers has the capacity to simultaneously handlemore than 100 research projects. Our focus is the de.velopment of small molecules for novel drug candi-dates, especially anti-tumor drugs, from innovativesynthesis routes to verification and optimization of production process.Furthermore,our center isequipped with a cutting-edge analysis and testingfacility, a standardized quality control frameworkand an intricately managed warehousing anoogistics system,These comprehensive resourcescollectively contribute to enhancing our customersresearch and developmental processes.

Reputable Manufacturer Supply Reliable Quality 1370001-96-9 On Stock

• Molecular Formula:C₁₁H₁₇BN₂O₂
• Molecular Weight:220.079
• Boiling Point:328.1±30.0 °C(Predicted) 
• PKA:1.66±0.16(Predicted) 
• Density:1.06±0.1 g/cm3(Predicted) 

1370001-96-9 Relevant articles

MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS

-

Paragraph 0878, (2020/10/09)

The invention relates to modulators of E...

SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS

-

Paragraph 00134; 00135, (2013/04/13)

Disclosed are azaindazole compounds of F...

BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1

-

Paragraph 00764-00765, (2013/12/03)

The present invention relates to compoun...

SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS

-

Page/Page column 52-53, (2012/04/17)

Disclosed are heteroaryl compounds of Fo...

1370001-96-9 Process route

1439-09-4

5-bromo-4-methylpyrimidine

73183-34-3

bis(pinacol)diborane

1370001-96-9

4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine

Conditions

Conditions	Yield
With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium acetate; In dimethyl sulfoxide; at 90 ℃; Inert atmosphere;	100%
With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium acetate; In 1,4-dioxane; at 25 - 80 ℃; for 12h; Inert atmosphere;	89%
With potassium acetate; dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; In dimethyl sulfoxide; at 90 ℃; for 24h;
With palladium bis[bis(diphenylphosphino)ferrocene] dichloride; potassium acetate; In 1,4-dioxane; at 90 ℃;

1370001-96-9

4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine

1428881-25-7

7-bromo-3-phenylbenzo[d]isoxazole

1428879-92-8

7-(4-methylpyrimidin-5-yl)-3-phenylbenzo[d]isoxazole

Conditions

Conditions	Yield
With tetrakis(triphenylphosphine) palladium(0); sodium carbonate; In 1,2-dimethoxyethane; ethanol; water; at 90 ℃; for 19h;	7.4%

1370001-96-9 Upstream products

• 
  1439-09-4

  5-bromo-4-methylpyrimidine

• 
  73183-34-3

  bis(pinacol)diborane

1370001-96-9 Downstream products

• 
  1428879-92-8

  7-(4-methylpyrimidin-5-yl)-3-phenylbenzo[d]isoxazole

• 
  1609579-44-3

  2-[5-(furo[3,2-c]pyridin-4-yloxy)-2-(4-methylpyrimidin-5-yl)phenyl]-2-methylpropanenitrile

• 
  1609581-87-4

  2-[5-hydroxy-2-(4-methylpyrimidin-5-yl)phenyl]-2-methylpropanenitrile